Neuroscientific Biopharmaceuticals Ltd has released a press release.
Positive Results in Multiple Sclerosis Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- 2021 Annual Report and Appendix 4E
- Results from Pulmonary Studies Clarification
- Pause in Trading
- Results from Pulmonary Studies
- Quarterly Update and Appendix 4C
Later from Neuroscientific Biopharmaceuticals
- NSB Receives R&D Advance & Overseas Finding
- Completion of Safety Pharmacology Studies
- Positive results in biomarker characterisation of Emtins
- Positive off-target safety assessment of EmtinB
- Successful completion of key studies in lead up to Phase I
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals